IG:HL7 diagnosis

Representation of Diagnosis based on the Clinical Document Architecture Rel.2 for Healthcare in Germany

Version 1.1

Representation of Diagnosis in specific Codesystems

ICD-10-GM-coded Diagnoses

Mapping of ICD-10-coded Diagnoses into HL7 v3

Representation of Diagnosis Confidence

Structured representations of ICD10-encoded diagnoses must support primary and secondary codes, code extensions, side localizations and confidence. The primary code represents the main disease. The secondary code extends the primary code and is either used to describe manifestations in organs ("asterisk") or the cause (etiology, e.g. which bacteria) of the main disease ("exclamation") In order to represent this dependency, an additional oberservation instance will be connected via the ActRelationship to that Observation instance containing the primary code.

So we have the following basic structure for ICD10-encoded diagnoses:

Specifying a Diagnosis using a Thesaurus Index

One more way of specifying a diagnosis is by using an index referring to an entry in a medical thesaurus.

Example: Mapping an Alpha-ID-coded Diagnosis

As an example, the diagnostic thesaurus „Alphabetische Verzeichnis zur ICD-10 GM“ (alphabetic directory of ICD-10 GM) is being used in Germany.

This directory allows to locate a verbose description of ICD-10 terms and to find the corresponding ICD-10 GM code.

The so-called Alpha-ID has been developed to process entries of that alphabetic directory.

It is an identification number for each textual entry in the "alphabetic directory".

In order to find this alpha-ID, a mapping file has been provided by DIMDI (www.dimdi.de).

The Alpha-ID is needed because in medical documentation, the descriptions of diagnoses need to be more differentiated than what ICD-10 codes actually can express.

Using the alpha-ID allows for a much finer granularity of diagnosis descriptions.[DIMDI,Alpha_Id].

Diagnosis Specification using Identifiers in a Nomenclature

One way of specififying a diagnosis is to use the code representing a diagnostic term in some medical nomenclature.

A well-known nomenclature in medicine is SNOMED-CT ("systematic nomenclature of medicine - clinical terms")

Compared to ICD-10 it has more concepts for diagnoses and mostly does not classify.

In general using a term of a nomenclature often preserves more information than using a term of a classification.

Classification is selecting a common representation for a set of concepts that are (under some aspect) considered similar.

As a result, classification reduces information, which is demonstrated by the following examples

I.e. as a part of clinical documentation of diagnosis the encoding using alpha-id or some identifier in a nomenclature would be preferred over using a classification like e.g. ICD-10.

The example shows concepts all being represented through the same ICD-10 code Q92.8 for 'Other specified trisomies and partial trisomies of autosomes'.

A simple comparison of codes from nomenclatures gives an example of missing clarity and precision of the ICD-10 classification.

Diagnosis	ICD-10 Code	Alpha-ID	Snomed CT	ID MACS
Imbalanced Insertion	Q92.8	I87548	254262003	M002405-D62839-58
Trisomy 22	Q92.8	I81282	205655003	M001897-D55549-58
Trisomy 20	Q92.8	I81283	53346000	M002406-D55530-58
Partial Trisomy a.n.k.	Q92.8	I81284	133849008	M001D1C-C78409-58

Table 6: Diagnoses in different coding systems

Precoordinated and Postcoordinated Concepts of a Nomenclature

For specifiying a diagnosis using a terminology there are two fundamental approaches:

The pre-coordinated approach selects a fixed term among a comprehensive list with representations for all possible concepts.

The list of all pre-coordinated terms limits the set of concepts which can be represented.

The post-coordinated approach constructs each term out of (more or less independently) encoded aspects of the concept to be represented.

The resulting term is the combination of the encoded aspects of the given concept.

ICD-10 is a good example of a pre-coordinated terminology, as it lists all the terms for the concepts it can represent.

The cross-asterisk extension to ICD-10 is an example of post-coordination.

More info can be found under the Terminfo project [Terminfo] of HL7 International.

Diagnosis by Thesaurus Index or Term within a Nomenclature

A term in a nomenclature is specified through the @value attribute of class Observation.

An example (SNOMED CT) of the structured representation looks like this:

  <observation moodCode="EVN" classCode="OBS">
  ...
  <value 
     xsi:type="CD" code="314888007" 
     codeSystem="2.16.840.1.113883.6.96"
     codeSystemName="SNOMED CT"
     displayName="Typ-II-Diabetes with diabetic cataract"/>
  ...
  </observation>

Attribute value.@code Index or Term in Nomenclature

CD CWE [1..1] The XML attribute @code keeps the index referring to an entry in a thesaurus or nomenclature.

Attribute value.@codeSystem OID of Nomenclature

UID [1..1] The XML attribute @codeSystem stores the OID of the thesaurus or nomenclature.

Attribute value.@displayName Text

ST [0..1] Through the XML attribute @displayName a plain text related to the index can be given.

Attribute value.@codeSystemName Name of Nomenclature

[0..1] The XML attribut @codeSystemName describes the name of the thesausrus or nomenclature.

Representation of Cancer Diagnosis

Introduction

In this chapter, diagnostic aspects of documentation of tumor diseases will be described. Different aspects of diagnostical descriptions of tumor diseases are described by ICD-O (Oncology) and by further classifications to document the expansion (tumor spread) or diseases stage, respectively, the latter one mostly being classified by the TNM-System.

Especially for hemato oncological diseases (Leukemias and Lymphomas), other systems (e.g. Ann-Arbor-Classification) are used. TNM-System discribes:

• Expansion of primary tumor (extent or, spread in distant organs repectively)
• Affection of lymph nodes in lymph flow area
• Existence of distant metastases.

For non-TNM–-classifiable diseases or in addition to the TNM-System there are a number of further classification systems:

• Ann Arbor
• Rai
• Binet
• CML-Phasen
• FAB
• Durie and Salmon
• Gleason-Score

Discriptions can be found here: http://www.med.uni-giessen.de/akkk/gtds/grafisch/doku/bd5f.htm http://www.tumorzentren.de/tl_files/dokumente/adt_basis.pdf

This list probably will be always incomplete because of the medical progress.

ICD-O

Third Edition of ICD-O [DIMDI, WHO] is the topical one. ICD-O consists of two axes, Topography- and Morphology-Axis. In ICD-O, tumor can be classified by

• Site
• Tissue Structure (Histology)
• Biological behaviour (Dignity)
• Tissue grading (mostly in two or four stages)

In this case, tissue structure and tissue grading is redundant. Precisely: The first four digits of morphology-code describe tissue-type. The fifth one describes biological behaviour (dignity-code):

• /0 = benign
• /1 = neoplasm with uncertain or unknown behaviour
• /2 = Cancer in situ
• /3 = malignant, primary tumor
• /6 = malignant, metastasis (not used in tumor documentation)
• /9 = malignant, uncertain wether primary tumor or a metastatic

The sixth digit describes grading, differentiation or phenotype (Histology/Pathology):

• 1 = Grade I, well differentiated (Low grade)
• 2 = Grade II, moderately differentiated (Intermediate grade)
• 3 = Grade III, poorly differentiated (High grade)
• 4 = Grade IV, undifferentiated (High grade)
• 9 = Grade IX, grade cannot be assessed

For Leukemias and Lymphomas, the sixth digit signifies the immunophenotype

• 5 = T-Cell
• 6 = B-Cell, Pre-B-Cell, B-Ancestor-Cell
• 7 = Null-Cell, Not-T-Cell-Not-B-Cell
• 8 = NK-Cell, Natural Killer Cell
• 9 = Determination of Cell Type was not accomplished, not specified or not applicable

TNM System describes

• Expansion of primary tumor (extent repectivly spread in distant organs)
• Affection of lymph nodes in lymph flow area
• Exisistence of distant metastasis

For the topography axis, there exists an (hierarchical) enlargement, the ‘localisation key’ (Wagner, G. (HRSG.): Tumorlokalisationsschlüssel, 5. Auflage, Springer Verlag, Berlin, Heidelberg, New York, Tokyo 1993), which can supply at some positions clinical relevant differentiation. The morphology axis is composed of a four-digit code for tissue basic structure, a characteristic number for dignity and an additional grading item. The key itself does not contain all possible combinations of histology and dignity, but points out those ones, for whome exist special discriptions. Vice versa not all combinations of basic structure and dignity are possible (so there is no ‘benign leukemia’). Not either there is a grading system available for all kinds of tumor. For some ones, additional information (for Example ‘Cell-line’) is used at the corresponding position.

Tumor Localization

For Tumor-Coding first of all, the site is important. It will be classified by the Topography -Axis of ICD-O. Topographical -Codes of ICD-10 are based on chapter II (Neoplasm –C 00 – C 97) of ICD-10. However, some of the topographical Codes of ICD-10 (Codes) are not used, because their content is discribed by histology- and digit-Codes of ICD-O. (e.g. Differentiation in situ/ infiltrated, melanoma vs. scin cancer).

Tumor Histology and Dignity

Furthermore, in ICD-O, tumor morphology i.e. tissue structure (histology) and biological behavior (dignity) is discribed by special Codes. Tumor histology is coded by a four-digit number, which is assumed of the morphology-axis of Standardized Nomenclature of Patholoy (SNOP). Dignity-Code is attendant on morphology-Code, seperated by /. Examples:

• 8060/0 squamous epithelium - papillomatose
• 8070/2 squamous epithelium – cancer in situ undifferentiated
• 8070/3 squamous epithelium – cancer undifferentiated
• 8070/6 squamous epithelium – cancer metastasis undifferentiated

Tumor Grading

Grading is derived from the comparison of primary tissue with the neoplasm of this tissue. There are five grading-degrees (s.o.) and further three degrees for Malignant Lymphoma. Registration of tumor grading is also provided in TNM.

Qualifier of Tumor Formular

ICD-O –Codes can be specified by the following qualifier:

Here ICD-O provides additionally the following codes for Lymphoma, which specify the Cell line: B-Cell, T-Cell, Null-Cell Lymphoma. ICD-O uses the Codes 1 – 9. A detailled System is discribed in Chapter 9 under 9.5.2 and 9.53.

Example

GRAPHIC IS MISSING

DisplayName is only available in correlation to qualifiers. According to ICD-O-3 formation rule there are much more discriptions possible as ICD-Catalog proposes.

TNM Classification

The TNM classification describes the expansion (spread) of the tumor , i.e. stadium and prognosis of the disease.

As a special feature, the TNM classification uses the same notation for all tumors but supports different interpretations for different entities.

As an example, a T3 for mamma carcinoma has a different interpretation then the stomach carcinoma.

The current edition is 7th which is valid since January 2010, which is a reason why many TNM-6- codes may still be in use. Therefore all TNM-codes should have a version identifier, because non translatable differences are in the different editions.

A simple overview can be found in http://de.wikipedia.org/wiki/TNM.

The T category will be used for the expansion of the primary tumor, where the stages T0, Tis, T1-T4 und TX are being used, the "higher" the number, the more progress is being diagnosed and the more adverse the prognosis.

T0 stands for "no primary tumor found" (e.g. because being eradicated by therapy) Tis stands for a very early (non-infiltrating) stage tumor (Tumor in situ) and TX stands for a diagnosis which can not judge the stage because of missing data

For some tumors subcategories like e.g. T2a, T2b have been defined.

The N-category classifies the affection of lymphatic nodes - usingN0, N1-N3, NX, where N0 means "no lymphatic node affected".

For some tumors, thisexclusion ("N0") requires the examination of a minimum amount of nodes.

The higher the N category the more severe is the lymphatic node affection.

If no sufficient data is available NX is being diagnosed.

The M category describes the existence of distant metastases, with the vallues of M0 (no metastases detectable), M1 (metastases detectable) and MX (insufficient data).

The TNM can be used according to clinical criteria (preoperative, cTNM) and according to the pathology findings (pTNM).

For many patients one single diagnoss will be made, either a cTNM or a pTNM, such that this type of finding must be distinguished.

This preoperative ("c" or no prefix) / pathology ("p") attribute can be captured independently for each of the T N M categories.

Therefore the typically used pTNM often meanes pTpNcM, because the spread of a timur can best be diagnosed through surgery while lymphatic spread only by pathology.

The prefix "r" describes remaining tumors (after non-disease intervals) and a prefix "y" if the classification was assessed after systemic or radiation treatment (ycTNM, ypTNM etc.).

For multiple Primary tumors the suffix "m" (or the number of tumors) will be put after the T-category value(T2(m), T2(5)).

Therefore a complete TNM formula looks like this:

There are voluntary components e.g. the certainty-Faktor (C-Factor)

Other components require pathology lab examination (L-, V- or Pn-Category)

• y-Symbol (y or empty, disgnosis after systematic or xray treatment)
• r-Symbol (r or empty, remainder)
• p/c/a-Symbol for pT-category (clinical or pathological)
• T-Category
• (m) for multiple localizations or number of tumors
• C-Factor for T-Category (certainty)

• L-Category
• V-Category
• Pn-Category
• p/c/a-Symbol for pN-Category (clinical or pathological)
• N-Category
• C-Factor for N-Category (certainty)

• p/c/a-Symbol für pM-Category
• M-Category
• C-Factor for M-Category (certainty)
• S-Kategorie (serological values, only for testicle tumors)
• UICC-Stadium (Grading via UICC 0 and I-IV together with

letter A, B and C for further classification).

For some tumors further modifiers are being documented as a suffix (mostly in parenthenses) like e.g. (sn), (mol-),(mol+).

In addition, the TNM supplement introduces innovative or "under test" extensions, which raises doubts whether ta full control of TNM entries.

Typical T-Categories (without pre-/suffices) are being listed in chapter "Sites"

Typical N-Categories (without pre-/suffices) are being listed in chapter "Nodes".

Typical M-Categories (without pre-/suffices) are being listed in chapter "Metastases".

9 Reference: DKFZ

Qualifiers of the Tumor Formula

Despite values for T,N and M the TNM formula may also contain various qualifiers. The following table gives an overview which qualifiers can be used for which information and where they are being used. This is case-sensitive !

a Autoptical c Clinical C C-Faktor (certainty) G histopathological Grading L Lymphatic vessel invasion m multiple Tumors M distant metastases N Regional lymphatic node metastases p pathological Pn perineural Invasion r Rezidiv tumor R Residual tumor after treatment sn Sentinel-Lymphatic nodes Stage Anatomic Stage-Grouping T Expansion (spreading) of Primary tumor V Venous invasion y Classifikation after initial multi-modal Therapy

Ann Arbor Classification

For lymphoma the TNM-classification does not make sense and therefore theso-called Ann-Arbor classification will be applied.

In this system, the stages I-IV are being distinguished, with an additional suffix letter - A meaning "no general symptoms" - B "with general symptoms" - E "extra-lymphatic organ affected" - S "spleen affected"

As with TNM, the Ann-Arbor classification distinguishes between cliniclal (cS) and pathological (pS) grading.

According to Durie & Salmon tere are gradings from I to III or the grades according to SWOG from 1-4 for the "Multiple Myeloma".

FIGO Stages

FIGO stages ignificantly overlap with the TNM classification, especially on the T-axis.

Therefore no details are being given here.

Gleason Score

The so-called Gleason-Score serves to classify the prostate carcinoma. The total numeric value is the sum of two indicators for • loss of differentiation (1-5) • growth pattern (1-5)

Resulting values range from 2 to 10 (also see Scores & Assessment DSTU).

Furthermore there is a more recent Gleason classification (according to Dhom, Müller and Helpap [Helpap 2002, Helpap2007]), which also requires to specify the procedure (esp. the two degrees) being used.

Papanikolaou

The so-called Pap-Test [Pap] is based on colored cell samples from the cervix and is used as an early indocator for cervical cancers.

WHO Grading

The so-called WHO Grading serves as an individual progonossi on the one hand and also is an indicator towards further treatment on the other hand.

Tumors of WHO Grade I and II in most cases can be treated by surgery alone, while tumors with WHO Grading III and IV normally need additional treatment by radiation or chemotherapie after surgery.

The grading looks like this:

Code	Codename	Meaning
I		benign,slow growth of tumor, very good prognosis
II		still benign, slow growth of tumor,tendency to recur
III		malignant,actively producing abnormal cells,tends to recur
IV		very malignant,fast growth,needs systemic therapy, bad prognosis

Table 9: WHO Grading (OID 1.2.276.0.76.5.394)

The fourth edition of the "World Health Organization (WHO) Classification of tumours of the central nervous system" (2007) lists all relevant tumor entities.

Also see "Brain Tumor Basics" (http://www.abta.org/sitefiles/sitepages/524309b806778d4f7b79044d97f324ea.pdf)

Conclusion

The following data of tumors can be represented by these respective classifications (through values and/or modifiers)

Concept	Classification
Tumor localisation	ICD-O
Morphology + dignity	ICD-O
Tissue differentiation ICD-O	ICD-O/TNM
type of stage codes (c,p,r,y)	TNM/Ann-Arbor
T Code + C Factor, multiplicity	TNM
M Code + C Factor, multiplicity	TNM
N Code + C Factor, multiplicity	TNM
Residual Tumor	TNM
stage grouping	TNM/Ann-Arbor/Durie&Salmon/SWOG

Terminology

Introduction

This chapter separates codes in use from normative specifications, in order to allow updates to such codes without having to rewrite the normative part. Therefore this chapter is just informative. Current codes have to be requested.

Due to pending third-party copy rights regarding some of the the following tables, the textual descriptions may not be given here such that the respective fields remain empty.

Overview of Value Sets

Value Sets	OID	Short Term	German	English
Tumors	1.2.276.0.76.11.1	uicctumor	ValueSet für Tumore in der Tumordokumentation	ValueSet for tumors in the cancer documentation
Nodes	1.2.276.0.76.11.2	uiccodes	ValueSet für Knoten in der Tumordokumentation	ValueSet for nodes in the cancer documentation
Metastases	1.2.276.0.76.11.3	uiccmetastasen	ValueSet für Metastasen in der Tumordokumentation	ValueSet for metastases in the cancer documentation
ResidualTumor	1.2.276.0.76.11.4	uiccresidualtumor	ValueSet für Residualtumor in der Tumordokumentation	ValueSet for residual tumor in the cancer documentation
Stage Classification	1.2.276.0.76.11.5	uiccstages	ValueSet für die Stadiengruppier ung in der Tumordokumentation	ValueSet for stages in the cancer documentation
Venous Invasion	1.2.276.0.76.11.6	uiccveneninvasion	ValueSet für die Veneninvasion in der Tumordokumentation	ValueSet for venous invasion in the cancer documentation
Lymphatic Invasion	1.2.276.0.76.11.7	uicclymphsysteminvasion	ValueSet für die Lymphsysteminvasion in der Tumordokumentation	ValueSet for the lymphatic system invasion in the cancer documentation
Perineural Invasion	1.2.276.0.76.11.8	uiccneuralscheideninvasion	ValueSet für die Neuralscheideninvasion in der Tumordokumentation	ValueSet for the perineural invasion in the cancer documentation
TNM Qualifier	1.2.276.0.76.11.9	uicctnmqualifier	ValueSet für die TNM-Qualifier in der Tumordokumentation	ValueSet for tnm qualifier in the cancer documentation
TNM Localisation for Tumor Documentation	1.2.276.0.76.11.10	uicclocalisation	ValueSet für die TNM-Seitenlokalisation in der Tumordokumentation	ValueSet for tnm localisation in the cancer documentation

Table 12: Value Sets

UICC 5. Edition (OID 2.16.840.1.113883.15.8) UICC 6. Edition (OID 2.16.840.1.113883.15.7) UICC 7. Edition (OID 2.16.840.1.113883.15.6)

Overview of Coding Schemata

Vocabulary Domain/Coding System	OID	Short Term
ICD10GM
ICD­10 GM Version 2012	1.2.276.0.76.5.409	icd10gm2012
ICD­10 GM Version 2011	1.2.276.0.76.5.388	icd10gm2011
ICD­10 GM Version 2010	1.2.276.0.76.5.384	icd10gm2010
ICD­10 GM Version 2009	1.2.276.0.76.5.356	icd10gm2009
ICD­10 GM Version 2008	1.2.276.0.76.5.330	icd10gm2008
ICD­10 GM Version 2007	1.2.276.0.76.5.318	icd10gm2007
ICD­10 GM Version 2006	1.2.276.0.76.5.311	icd10gm2006
ICD­O
ICD­O­3	2.16.840.1.113883.6.43.1	icd­o­3
ICD­O­DA­1978	n.a.
ICD­O­DA­2002	n.a.
TNM
C­Faktor	1.2.276.0.76.5.341	c­faktor­tumor
TNM 5. Edition	2.16.840.1.113883.15.8	tnm5
TNM 6. Edition	2.16.840.1.113883.15.7	tnm6
TNM 7. Edition	2.16.840.1.113883.15.6	tnm7
Dignity	1.2.276.0.76.5.335	dignitaet­tumor
Cell­ Type	1.2.276.0.76.5.413
Validity R­Classification	1.2.276.0.76.5.414
Existence of Residual Tumor	1.2.276.0.76.5.415
Tumor Diagnoses	1.2.276.0.76.5.334	tumordiagnosen
Grading	1.2.276.0.76.5.336	grading_tumor
­Localisation of Metastases	1.2.276.0.76.5.401
Scores
Gleason­Score
Gleason­Score: Loss of Differentiation	1.2.276.0.76.5.402
Gleason­Score: Growth Pattern	1.2.276.0.76.5.403
Gleason­Score: Grading	1.2.276.0.76.5.404
Ann­Arbor	1.2.276.0.76.5.405
Papanikolaou: Grading	1.2.276.0.76.5.406
Alpha­ID
Alpha­ID 2012	1.2.276.0.76.5.408	alphaid2012
Alpha­ID 2011	1.2.276.0.76.5.387	alphaid2011
Alpha­ID 2010	1.2.276.0.76.5.383	alphaid2010
Alpha­ID 2009	1.2.276.0.76.5.355	alphaid2009
Alpha­ID 2008	1.2.276.0.76.5.329	alphaid2008
Alpha­ID 2007	1.2.276.0.76.5.316	alphaid2007
Alpha­ID 2006	1.2.276.0.76.5.309	alphaid2006
MeSH
MeSH	2.16.840.1.113883.6.177.5	MSHGER
Snomed CT
SNOMED CT	2.16.840.1.113883.6.96	SNOMED CT
ID Macs
ID Macs	1.2.276.0.76.5.305	id_macs
Typing Diagnosis	1.2.276.0.76.5.342

Table 13: Coding Schemata

Diagnosis Types In Germany

The following codes are being used for typing of diagnoses. This table is a pragmatic collection of the current state-of-the-art in german systems. An international classification is not available at this time.

Code	Meaning
DX	Diagnosis, not specified any further
RFFDX	Referral Diagnosis
ENTDX	Entry Diagnosis
TRFDX	Transfer Diagnosis
ADMDX	Admittance Diagnosis
CDDX	Clinical Department’s Diagnosis
CDXDX	Clinical Department’s extra Diagnosis
CDTDX	Clinical Department’s Treatment Diagnosis
CDDISDX	Clinical Department’s Discharge Diagnosis
CDADMDX	Clinical Department’s Admittance Diagnosis
SUCCDX	Successive Diagnosis (with continuing sick leave)
DISDX	Discharge Diagnosis
TDX	Transfer Diagnosis
PERMDX	Permanent Diagnosis
APERMDX	Anamnestic Permanent Diagnosis
BPERMDX	Treatment-related Permanent Diagnosis
EMERDX	Emergency-related Diagnosis
REIMDX	Reimbursement Diagnosis
POSTOPDX	Post-operative Diagnosis
PREOPDX	Pre-operative Diagnosis
ADR	UAW ­Observed Unwanted Side Effects
ADRPD	UAW Main Disease
ADRCCD	UAW Side Disease
IFSGDX	If–G ­Diagnoses
IFSGSUSPDX	If–G ­Suspicious Diagnoses
IFSGDD	If–G ­Differential Diagnoses
COD	Cause of Death (fatal disease)
CCCOND	Accompanying Diseases
EXTCS	External Cause
NEO	Neoblasts
UAE	Unwanted Medication Event
UAW	Unwanted Medication Effect12
CAREDX	Care Diagnosis
SYMDX	Symptom
OTHDX	Miscellaneous Diagnosis

Table 14: Diagnosis Types (OID 1.2.276.0.76.5.342)

ICD-O Codes

Dignity

Dignity refers to a tumor property related to their biological behavior in the body. 13

Meaning	Code
0	benign
1	Neoplasm with uncertain or unknown behaviour
2	Carcinoma in situ
3	malign, Primary Tumor
6	malign, Metastasis
9	malign, not differentiated between Primary Tumor or Metastasis

Table 15: Dignity Codes (OID 1.2.276.0.76.5.335)

12 In this case, a cause has to be documented along with the diagnosis – but that is not covered in this implementation guide. It also has to be clarified whether such diagnosis is equal to “suspicious for”. 13 DIMDI www.dimdi.de ICD10GM, ICDO3

Grade of Differentiation/Grading

The following table lists possible gradings. The entity column lists to what tumor entities these grades apply. ref.14

Code	Description	German	Entity
0	Primary acquired melanosis		Malignant Melanoma of Conjunctiva
1	well differentiated	Gut differenziert	all but Prostata, Malignant Melanoma of Conjunctiva
	Well differentiated (slight anaplasia) (Gleason 2­4)		Prostata
	Malignant melanoma arising from a naevus		Malignant Melanoma of Conjunctiva
2	moderately differentiated	Mäßig differenziert	all but Prostata, Malignant Melanoma of Conjunctiva
	Moderately differentiated (moderate anaplasia) (Gleason 5–6)		Prostata
	Malignant melanoma arising from primary acquired melanosis		Malignant Melanoma of Conjunctiva
3	poorly differentiated	Schlecht differenziert	all but Prostata, Penis, Kidney, Renal Pelvis and Ureter, Urinary Bladder, Urethra, Malignant Melanoma of Conjunctiva
	Malignant melanoma arising de novo		Malignant Melanoma of Conjunctiva
3­4	Poorly differentiated/ undifferentiated (marked anaplasia) (Gleason 7– 10)		Prostata
	Poorly differentiated/ undifferentiated		Penis, Kidney, Renal Pelvis and Ureter, Urinary Bladder, Urethra
4	undifferentiated	Undifferenziert	all but Prostata, Penis, Kidney, Renal Pelvis and Ureter, Urinary Bladder, Urethra, Malignant Melanoma of Conjunctiva
9			Grading not performed, not given or not applicable
L	low malignity (G1­G2)	Niedriggradig maligne (G1­G2)
M	intermediate malignity (G2­G3)	Mittelgradig maligne (G2­G3)
H	high malignity (G3­G4)	Hochgradig maligne (G3G4)
B	Borderline	Grenzfall
X	grade of differentiation cannot be assessed	Differenzierungs­grad nicht be­stimmbar

This Grading may either be a qualifier in a containing ICDO or be documented as a component in a stand-alone code.

Table 16:Grade of Differentiation/Gradings (OID 1.2.276.0.76.5.336) 14 DIMDI www.dimdi.de ICD¬O¬3

Cell Type

This qualifier identifies the immune phenotype related to a lymphoma.

Code	Meaning	Explanation
T	T­ cell type	affects T ­lymphocytes
B	B­ cell type	affects B lymphocytes
N	Null cell type	NHL  Th0, null cell type lymphoma (and T-cell)
K	Natural­ Killer cell type	affects NK­ cells: rare lymphoma, mostly in nose or of nasal type
X		not determineable (undifferentiated lymphoma)
9		affected cell type determination not performed, not specified or not applicable
U		unknown, nullFlavor=UNK

Table 17: Lymphoma-Affected Cell Type (OID 1.2.276.0.76.5.413)

Validity of R Classification

This qualifier documents the focus of the Residual¬ Classification15.

Code	Meaning	Explanation
L	locoregionary tumor	nearby tumor(s)
M	distant metastasis	distant secondary tumors
G	overall phenomenon

Table 18: Validity of R-Classifikation (OID 1.2.276.0.76.5.414) 

15 Altmann based on TNM V7, Giessen, 2010

Existence of Residual Tumor

This qualifier indicates, where a Residual Tumor exists ref. 16.

Code	Meaning	Explanation
L	locoregionary tumor	nearby tumor(s)
F	distant metastasis	distant secondary tumors
B	both
U	unknown	nullFlavor=UNK

Existence of residual Tumor

16 Dudeck J. Basisdokumentation für Tumorerkrankte. Giessen. 1999.

Codes for TNM-Classification

The TNM classification according to UICC is being a codesystem as a whole. Therefore all tables share the same OID for documentation purposes. An easy way to handle this is the definition of value sets, each with the respective permitted values. Each code may only be used in some documentation if the respective UICC edition is checkmarked in our table– which states that the respective code is a part of that edition .

Tumors

This section lists known T-Categories ref. 17 (without representing possible extensions). Descriptions vary with the related entity. Codes shall be used along with tumor diagnosis, as one code may have different meanings. (e.g. T1 may refer to 23 cm or 24 cm).

Code	Description	Explanation	5.	6.	7.
Ta			X	X	X
Tis	Carcinoma in situ	non invasive	X	X	X
T0	No evidence of primary tumour			X	X
T1			X	X	X
T1mic		micro invasion	X	X	X
T1a			X	X	X
T1a1			X	X	X
T1a2			X	X	X
T1b			X	X	X
T1b1			X	X	X
T1b2			X	X	X
T1c			X	X	X
T1d					X
T2			X	X	X
T2a			X	X	X
T2a1					X
T2a2					X
T2b			X	X	X
T2c			X	X	X
T2d					X
T3			X	X	X
T3a			X	X	X
T3b			X	X	X
T3c			X	X	X
T3d				X	X
T4			X	X	X
T4a			X	X	X
T4b			X	X	X
T4c			X	X	X
T4d			X	X	X
T4e					X
TX	Primary tumor cannot be assessed	Stage of primary tumor cannot be determined

Table 20: (T) Tumor Codes Value Set (OID 1.2.276.0.76.11.1) 17 TNM 5.,6.,7. Edition

Nodes

Any code for involvement of lymph nodes shall only be used together with tumor diagnosis.

				UICC	UICC	UICC
Code	Description	Meaning	Entity	5.	6.	7.
N0	No regional lymph node metastasis	no lymph node affected	all	X	X	X
N1				X	X	X
N1mi	Bilateral regional lymph node metastasis		vulva		X	X
N1a			all	X	X	X
N1b				X	X	X
N1b1				X
N1b2				X
N1b3				X
N1b4				X
N1c					X	X
N2				X	X	X

Table 21: (N) Lymph Node Codes Value Set (OID 1.2.276.0.76.11.2)

Metastasis

Code describing distant metastases shall only be used together with tumor diagnosis.

Code	Description	German	Entity	5.	6.	7.
				UICC	UICC	UICC
M0	No distant metastasis	Fernmetastasen nicht vorhanden	all	X	X	X
M1	Distant metastasis	Fernmetastasen vorhanden	all	X	X	X
M1a			only oesophagus / prostate	X	X	X
M1b			only oesophagus / prostate	X	X	X
M1c				X	X	X
M1d						X
M1e						X
MX	Distant metastasis cannot be assessed		all	X	X	X

Table 22: (M) Metastasis Code Value Set (OID 1.2.276.0.76.11.3)

Residual Tumor

Code	Description	German
R0	No residual tumour	kein Residualtumor
R1	Microscopic residual tumour	nur mikroskopisch Residualtumor nachweisbar
R2	Macroscopic residual tumour and	makroskopischer Residualtumor und
R2a	microscopically not confimed	­mikroskopisch nicht bestätigt
R2b	microscopically confimed	­mikroskopisch bestätigt
RX	Presence of residual tumour cannot be assessed	Unbekannt

Table 23: Residualtumor Codes Value Set (OID 1.2.276.0.76.11.4)

Stage grading as of UICC

Code	Description	Meaning	5.	6.	7.
			UICC
okk		TX, N0, M0	X	X	X
0	Carcinoma in situ	Tis, N0, M0	X	X	X
0a			X	X	X
0is			X	X	X
I				X	X
IA		T1, N0, M0	X	X	X
IA1			X	X	X
IA2			X	X	X
IB		T2, N0, M0	X	X	X
IB1			X	X	X
IB2			X	X	X
IC			X	X	X
II			X	X	X
IIA		T1, N1, M0	X	X	X
IIA1					X
IIA2					X
IIB		T2, N1, M0	X	X	X
IIC		T3, N0, M0	X	X	X
III			X	X	X
IIIA		T1, N2, M0	X	X	X
IIIA		T2, N2, M0
IIIA		T3, N1,2, M0
IIIB		T4, each N, M0	X	X	X
IIIB		each T, N3, M0
IIIC			X	X	X
IS			X	X	X
IV		each T, each N, M1	X	X	X
IVA			X	X	X
IVB			X	X	X
IVC			X	X	X
not defined			X	X	X
not recommended				X	X

Table 24: Stage Classification ref. 18 Value Set (OID 1.2.276.0.76.11.5)

18 In: Schmoll HJ, Höffken K, Possinger K eds. Kompendium Internistische Onkologie. „Collection of Internistic Oncology “. Springer. 4. Edition; 2006

Venous Invasion

Code	Description	German
V0	no venous invasion	keine Veneninvasion
V1	microscopic venous invasion	mikroskopische Veneninvasion
V2	macroscopic venous invasion	makroskopische Veneninvasion
VX	venous invasion cannot be assessed	Veneninvasion nicht feststellbar

Table 25: Venous Invasion Code Value Set (OID 1.2.276.0.76.11.6)

Lymphatic System Invasion

Code	Description	German
L0	no lymphatic invasion	keine Lymphsysteminvasion
L1	lymphatic invasion	Lymphsysteminvasion
LX	lmphatic invasion cannot be assessed	Lymphsysteminvasion nicht fest­stellbar

Table 26: Lymphatic Invasion Codes Value Set (OID 1.2.276.0.76.11.7)

Perineural Invasion

Code	Description	German
Pn0	no perineural invasion	keine perineurale Invasion
Pn1	Perineural invasion	perineurale Invasion
PnX	unknown	Unbekannt

Table 27: Perineural Invasion Code Value Set (OID 1.2.276.0.76.11.8)

Qualifier

Code	Description	German
c	Assessment according to clinical criteria	Beurteilung nach klinischen Kriterien
p	according to the pathological results	nach dem pathologischen Befund
r	TNM result of recurrent tumor	TNM­Befund für Rezidivtumor
y	Classification of initial multimodal therapy	Klassifikation nach initialer multi­modaler Therapie

Table 28: TNM-Qualifier Value Set (OID 1.2.276.0.76.11.9)

Certainty

Code	Description of Evidence	German
C1	Evidence from standard diagnostic means (e.g., inspection, palpation, and standard radiography, intraluminal endoscopy for tumours of certain organs)	Nachweis durch diagnostische Standardmethoden (Inspektion, Palpation, einfache Röntgenaufnahmen)
C2	Evidence obtained by special diagnostic means (e.g., radiographic imaging in special projections, tomography, computerized tomography [CT], ultrasonography, lymphography, angiography,scintigraphy,magnetic resonance imaging [MRI],endoscopy, biopsy, and cytology)	Nachweis durch spezielle klinische diagnostische Methoden einschließlich Computertomogramm, Magnet­Resonanz­Tomographie
C3	Evidence from surgical exploration, including biopsy and cytology	Nachweis durch Operation, einschließlich Biopsie und Zytologie
C4	Evidence of the extent of disease following definitive surgery and pathological examination of the resected specimen	Nachweis durch operative Behandlung mit pathologischer Untersuchung der entnommenen Gewebeteile
C5	Evidence from autopsy	Nachweis durch Autopsie

Table 29: Certainty Factor Codes (OID 1.2.276.0.76.5.341)

Localisation of Distant Tumours / Metastases

Code	Description	German	Explanation
PUL	Pulmonary	Pulmonal	Lungenmetastase
OSS	Osseous	Ossär	Knochenmetastase
HEP	Hepatic	Hepatisch	Lebermetastase
BRA	Brain	Cerebral	Hirnmetastase
LYM	Lymph Nodes	Lymphonodulär	Lymphknotenmetastase
OTH	Others	Andere	Andere Metastase
MAR	Bone Marrow	Medullär	Knochenmarkmetastase
PLE	Pleura	Pleural	RippenfellMetastase
ADR	Adrenals	Adrenal	Nebennierenmetastase
SKI	Skin	dermal	Hautmetastase

Table 30: Metastases Localisation Codes (OID 1.2.276.0.76.5.401)

Codes for Gleason Score

The Gleason Grading system helps evaluating the prognosis of men with prostate cancer, as a part of a strategy of prostate cancer staging which predicts prognosis and guides therapy. The Gleason score is based on microscopic findings.

Code	Description	German
1	Round to oval equal individual glands, lying close to each other, sharply demarcated from the surrounding area	Runde bis ovale gleich große Einzeldrüsen, dicht nebeneinander liegend, scharf gegen die Umgebung abgegrenzt
2	Slightly less uniform single glands, separated by small amounts of stroma, less sharply defined tumor margin	Etwas weniger uniforme Einzeldrüsen, getrennt durch geringe Mengen von Stroma, weniger scharf begrenzter Tumorrand
3	a) Irregularly large and irregularly shaped glands, usually with abundant stroma, sometimes also stored tightly irregular and indistinct tumor border	Unregelmäßig große und unregelmäßig gestaltete Drüsen mit gewöhnlich reichlicherem Stroma, gelegentlich auch dicht gelagert, unregelmäßige und unscharfe Tumorgrenze
	b) Papillary or cribriform structures, sometimes in large gang­like formations	Papilläre oder kribriforme Strukturen, z.T. in großen gangähnlichen Bildungen
4	"a) Large irregular Epithelformationen by glandular fusion (""fused glands"") and branched glands with irregular infiltration into the surrounding area "	Große unregelmäßige Epithelformationen durch Drüsenverschmelzung („fused glands“) sowie verzweigte Drüsen mit unregelmäßiger Infiltration in die Umgebung
	b) Adenocarcinoma with prominent clear cytoplasm similar to clear cell adenocarcinomas of the kidney	Adenokarzinom mit ausgeprägt klarem Zytoplasma ähnlich hellzelligen Adenokarzinomen der Niere
5	a) Circumscribed round epithelial clusters with mostly solid and cribriform construction, usually with central necrosis	Scharf begrenzte runde Epithelhaufen mit meist solidem und kribriformem Bau, gewöhnlich mit zentraler Nekrose
	(comedo carcinoma­like)	(komedo­karzinomähnlich)
	b) Irregularly shaped formations of an undifferentiated carcinoma, which only just discernible glandular formation or is identified vacuoles (signet ring­like) than adenocarcinoma	Unregelmäßig begrenzte Formationen eines undifferenzierten Karzinoms, das nur durch gerade noch erkennbare Drüsenbildung oder Vakuolen (siegelringähnlich) als Adenokarzinom zu identifizieren ist

Table 31: Loss of Differentiation according to Gleason Score ref. 19 (OID 1.2.276.0.76.5.402)

Documentation by the GleasonSum (Gleason¬Score) as the sum of the two most dominating findings: Uniformly structured tumors: two times the points of above table. Non-uniformly structured tumors: points for the dominating share of findings (so-called primary grading) + points for second-largest share (secondary grading), if punch biopsy show more than two grades, the second component will be based on the most adverse component found.

19: Dt. Gesellschaft f. Urologie e.V.

Ann Arbor Codes

The tumor staging system for lymphomas.

Principal Stages

Code	Description
I	cancer is located in a single region, usually one lymph node and the surrounding area
II	cancer is located in two separate regions, an affected lymph node or organ and a second affected area, and that both affected areas are confined to one side of the diaphragm
III	cancer has spread to both sides of the diaphragm, including one organ or area near the lymph nodes or the spleen
IV	diffuse or disseminated involvement of one or more extralymphatic organs

Table 33: Ann Arbor (OID 1.2.276.0.76.5.405)

Modifiers for Constitutional Symptoms

Code	Description
A	absence of constitutional symptoms is denoted by adding an ""A""
B	presence of constitutional (B-type) symptoms is denoted by adding a ""B""

Table 34: Ann Arbor constitutional symptoms (OID 1.2.276.0.76.5.416)

Modifiers for Spread of Tumor

Code	Description
E	disease is ""extranodal"" (not in the lymph nodes) or has spread from lymph nodes to adjacent tissue.
S	the disease has spread to the spleen.
X	the largest deposit is >10 cm large (""bulky disease""), or the mediastinum is wider than 1/3 of the chest on a chest X-ray.

Table 35: Ann Arbor Extensions for Spreading in Organs Code Set (OID 1.2.276.0.76.5.417)

Papanicolaou Coding

Results of the so-called Pap-Test

Code	Meaning
Pap0	non representative sample
PapI	normal cell findings
PapII	atypical, benign disorder, infection, metaplasia, atrrophy, bacteria, viruses,
PapIIw	insufficient samples
PapIII	cell proliferation and atypic cells
PapIIID	dysplastic , mostly with HPV infection
PapIIIG	moderate/severe dyskaryosis and/or dysplasia
PapIV	biopsy sample and histological clarification required
PapIVa	carcinoma in situ
PapIVb	single certain tumour cells, carcinoma very certain
PapV	many certain tumour cells, carcinoma certain, cellular changes suggestive of invasive squamous carcinoma, and cellular changes indicative of adenocarcinoma of the uterine cervix and other invasive cancer.

Table 36: Grading according to Papanicolaou (OID 1.2.276.0.76.5.406)